Exercise-based cardio-oncology rehabilitation for cardiotoxicity prevention during breast cancer chemotherapy: The ONCORE randomized controlled trial
- PMID: 38395212
- DOI: 10.1016/j.pcad.2024.02.002
Exercise-based cardio-oncology rehabilitation for cardiotoxicity prevention during breast cancer chemotherapy: The ONCORE randomized controlled trial
Abstract
Background: Breast cancer (BC) treatment with anthracyclines and/or anti-human epidermal growth factor receptor-2 (HER2) antibodies is associated with an increased risk of cardiovascular disease complications, including cancer therapy-related cardiac dysfunction (CTRCD). While Cardio-Oncology Rehabilitation (CORe) programs including exercise have emerged to minimize these risks, its role in preventing CTRCD is unclear.
Objectives: We investigated the effectiveness of an exercise-based CORe program in preventing CTRCD [left ventricular ejection fraction (LVEF) drop ≥10% to a value <53% or a decrease >15% in global longitudinal strain (GLS)]. Secondary outcomes examined changes in cardiac biomarkers, physical performance including peak oxygen consumption, psychometric and lifestyle outcomes. Safety, adherence, and patient satisfaction were also assessed.
Methods: This is a randomized controlled trial including 122 early-stage BC women receiving anthracyclines and/or anti-HER2 antibodies, randomized to CORe (n = 60) or usual care with exercise recommendation (n = 62). Comprehensive assessments were performed at baseline and after cardiotoxic treatment completion. The average duration of the intervention was 5.8 months.
Results: No cases of CTRCD were identified during the study. LVEF decreased in both groups, but was significantly attenuated in the CORe group [-1.5% (-2.9, -0.1); p = 0.006], with no changes detected in GLS or cardiac biomarkers. The CORe intervention led to significant body mass index (BMI) reduction (p = 0.037), especially in obese patients [3.1 kg/m2 (1.3, 4.8)]. Physical performance and quality-of-life remained stable, while physical activity level increased in both groups. No adverse events were detected.
Conclusions: This study suggests that CORe programs are safe and may help attenuate LVEF decline in BC women receiving cardiotoxic therapy and reduce BMI in obese patients.
Keywords: Breast cancer; Cardio-oncology rehabilitation; Cardiotoxicity; Cardiovascular prevention; Exercise.
Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors have declared that they have no relationships relevant to the contents of this paper to disclose.
Similar articles
-
A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol.BMC Cardiovasc Disord. 2021 Apr 7;21(1):165. doi: 10.1186/s12872-021-01970-2. BMC Cardiovasc Disord. 2021. PMID: 33827450 Free PMC article.
-
Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.J Am Heart Assoc. 2020 Jan 21;9(2):e014708. doi: 10.1161/JAHA.119.014708. Epub 2020 Jan 21. J Am Heart Assoc. 2020. PMID: 31959034 Free PMC article.
-
Phenotypes of Myocardial Dysfunction on Serial Echocardiography and CMR in Women With Early-Stage Breast Cancer.JACC Cardiovasc Imaging. 2025 May;18(5):540-553. doi: 10.1016/j.jcmg.2024.12.010. Epub 2025 Mar 19. JACC Cardiovasc Imaging. 2025. PMID: 40117396
-
Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis.JAMA Cardiol. 2019 Oct 1;4(10):1007-1018. doi: 10.1001/jamacardio.2019.2952. JAMA Cardiol. 2019. PMID: 31433450 Free PMC article.
-
Cardiotoxic Effect of Modern Anthracycline Dosing on Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis of Placebo Arms From Randomized Controlled Trials.J Am Heart Assoc. 2021 Mar 16;10(6):e018802. doi: 10.1161/JAHA.120.018802. Epub 2021 Mar 4. J Am Heart Assoc. 2021. PMID: 33660514 Free PMC article.
Cited by
-
Interaction of Body Mass Index and Glycemic Status on Cardiovascular Outcomes in Patients With Cancer Treated With Anthracyclines.J Am Heart Assoc. 2025 Jun 3;14(11):e040876. doi: 10.1161/JAHA.124.040876. Epub 2025 May 22. J Am Heart Assoc. 2025. PMID: 40401613 Free PMC article.
-
Cardiovascular toxicity of breast cancer treatments: from understanding to enhancing survivorship care.ESMO Open. 2025 Jun;10(6):105128. doi: 10.1016/j.esmoop.2025.105128. Epub 2025 Jun 2. ESMO Open. 2025. PMID: 40460678 Free PMC article. Review.
-
Cancer Therapy-Related Cardiac Dysfunction: Strategies for Enhancing Cardiac Recovery.Methodist Debakey Cardiovasc J. 2024 Aug 20;20(4):109-112. doi: 10.14797/mdcvj.1430. eCollection 2024. Methodist Debakey Cardiovasc J. 2024. PMID: 39184162 Free PMC article. Review.
-
Cardiotoxicity in Elderly Breast Cancer Patients.Cancers (Basel). 2025 Jun 30;17(13):2198. doi: 10.3390/cancers17132198. Cancers (Basel). 2025. PMID: 40647496 Free PMC article. Review.
-
Exercise Interventions in Breast Cancer: Molecular Mechanisms, Physical Benefits, and Practical Recommendations.Medicina (Kaunas). 2025 Jun 27;61(7):1167. doi: 10.3390/medicina61071167. Medicina (Kaunas). 2025. PMID: 40731797 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous